Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for pancreatic cancer allows life-saving surgery

08.12.2005


A new treatment for pancreatic cancer developed by clinical researchers of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center substantially reduces the size of tumors and lowers the risk of local recurrence of the disease. Fifty percent of patients in the study responded to therapy--one of the highest response rates ever seen with pancreatic cancer. Results of the study were published in the December 2005 issue of the Annals of Surgical Oncology.



Researchers, led by oncologist and principal investigator J. Marc Pipas, M.D., were able to reduce the size of tumors so significantly that a number of patients who previously had been categorized as borderline or inoperable could have their tumors surgically removed.

Surgery, and the complete removal of the tumor, is the only curative hope for people with pancreatic cancer, the fourth leading cause of cancer death in the U.S., according to the National Cancer Institute. NCI estimates that of the 32,180 new cases of pancreatic cancer in 2005, 31,800 will die.


The overall five-year survival rate for pancreatic cancer is only 4%, but for patients whose tumors can be completely removed, long-term survival jumps to 18-24%. Detecting the tumor in an early stage is crucial, but pancreatic cancer has few symptoms and is often diagnosed only after the cancer has grown into surrounding tissue or metastasized, making surgery impossible.

"The only way to cure these tumors is to remove them completely," explains Pipas. "You try to do something to make sure there is no microscopic disease left. If you can’t remove it, the prognosis is poor."

Traditional treatment for pancreatic cancer is surgery followed by chemotherapy and radiation. The treatment Pipas developed reverses the treatment steps. He administers chemotherapy and radiation in combination first, in order to reduce the size of the tumor and increase the possibility of surgery. The reverse treatment regimen results in many tumors previously considered borderline or inoperable shrinking to a size where they could be surgically removed. In the Norris Cotton Cancer Center trial, 24 patients were treated with short course, high dose chemotherapy of docetaxel and gemcitabine, followed by a combination of radiation and twice-weekly low-dose gemcitabine. Chemotherapy doses in this trial were higher than previously attempted.

Results showed that 50% of tumors shrank by at least a third, including complete disappearance of a tumor in a patient who previously had been judged inoperable. No tumors progressed during treatment.

The ability to shrink a pancreatic tumor is important because in order to eradicate the cancer, the tumor must be small enough to be completely removed without damaging major blood vessels surrounding the pancreas. Seventeen patients in the study underwent surgery, including nine previously considered inoperable or borderline operable. Subsequent follow-up showed that no patient whose tumor was surgically removed had a local recurrence of the disease, and no patient whose disease was considered inoperable had local progression.

Because the treatment Pipas and his team developed is allowing more patients the option of surgery, it is now the standard treatment for pancreatic cancer at the Norris Cotton Cancer Center.

In a new study, Pipas is using gemcitabine and radiation in combination with cetuximab (Erbitux®), an antibody treatment. Norris Cotton Cancer Center is the only center testing this treatment for pancreatic cancer.

"Our goal for therapy is more people to complete resection," explains Pipas. "That’s going to be the first step to curing patients."

Jane D’Antonio | EurekAlert!
Further information:
http://www.dartmouth.edu/
http://www.hitchcock.org

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>